Sangamo Therapeutics is a clinical-stage biotech company that focuses on creating genomic medicines for life-changing treatments, using gene therapy, cell therapy, genome editing, and genome regulation. The company has developed various therapies for hemophilia A, Fabry disease, sickle cell disease, Parkinson's disease, and neuromuscular disease in different stages of clinical trials. With several strategic partnerships, they work on making a significant impact in the field of genomic medicine.